-
1 Comment
PZ Cormay S.A. is currently in a long term downtrend where the price is trading 3.8% below its 200 day moving average.
PZ Cormay S.A.'s total revenue sank by 24.2% to $14M since the same quarter in the previous year.
Its net income has increased by 22.4% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 18.9% to $-5M since the same quarter in the previous year.
Based on the above factors, PZ Cormay S.A. gets an overall score of 1/5.
| Exchange | WAR |
|---|---|
| CurrencyCode | PLN |
| ISIN | PLCMRAY00029 |
| Sector | Technology |
| Industry | Scientific & Technical Instruments |
| Market Cap | 49M |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Beta | 0.88 |
| Dividend Yield | None |
PZ Cormay S.A. develops, manufactures, and sells diagnostic reagents in Poland. It offers testing products for clinical chemistry, electrophoresis, hematology, veterinary, coagulology, blood group serology, immunology, immunochemistry, molecular biology, sampling, oncological surgery, and general analytics, as well as vacuum blood collection system. The company offers its products under the Orphée and Diesse brand names. The company also exports its products to approximately 150 countries, including Germany, Austria, France, Greece, Turkey, Indonesia, Malaysia, England, China, Portugal, Czech Republic, Slovakia, Ukraine, Latvia, Bulgaria, and India. PZ Cormay S.A. was founded in 1985 and is based in Lomianki, Poland.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CRM.WAR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
